Valuation: Starpharma Holdings Limited

Market Cap 401M 281M 247M 233M 212M 398M 26.96B 2.79B 1.08B 13.77B 1.06B 1.03B 44.27B P/E 2027 *
420x
P/E 2028 * 29x
Enterprise Value 354M 249M 218M 206M 188M 352M 23.85B 2.47B 956M 12.19B 934M 914M 39.16B EV / Sales 2027 *
14.8x
EV / Sales 2028 * 9.12x
Free-Float
70.11%
Yield 2027 *
-
Yield 2028 * -
1 day+3.07%
1 week+5.00%
Current month+16.67%
1 month+15.86%
3 months+20.86%
6 months+80.65%
Current year+133.33%
1 week 0.77
Extreme 0.77
0.85
1 month 0.7
Extreme 0.705
0.85
Current year 0.33
Extreme 0.33
0.85
1 year 0.22
Extreme 0.22
0.85
3 years 0.08
Extreme 0.082
0.85
5 years 0.08
Extreme 0.082
1.49
10 years 0.08
Extreme 0.082
2.52
Manager TitleAgeSince
Chief Executive Officer - 08/01/2024
Director of Finance/CFO - 03/04/2023
Human Resources Officer - 01/06/2022
Director TitleAgeSince
Chairman 81 13/06/2014
Director/Board Member 55 01/03/2020
Director/Board Member - 01/08/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/11/26 A Buy

Chairman

350,001 0.0734%
8/11/26 A Buy

Director

22,741 0.0048%
8/11/26 A Buy

Chief Executive Officer

16,667 0.0035%
Change 5-day change 1-year change 3-year change Capi.($)
+3.07%+5.00%+281.82%+425.00% 281M
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
+0.83%+0.55%+34.64%+99.83% 187B
0.00%-10.14%-27.40%-61.08% 171B
Average +0.71%+1.17%+55.30%+86.12% 363.86B
Weighted average by Cap. +0.27%+1.32%+40.44%+68.24%

Financials

2027 *2028 *
Net sales 24M 16.86M 14.79M 13.97M 12.73M 23.83M 1.62B 167M 64.74M 825M 63.28M 61.92M 2.65B 37.5M 26.34M 23.11M 21.83M 19.89M 37.23M 2.52B 261M 101M 1.29B 98.88M 96.74M 4.14B
Net income 1.2M 843K 740K 698K 636K 1.19M 80.77M 8.36M 3.24M 41.27M 3.16M 3.1M 133M 14.7M 10.32M 9.06M 8.56M 7.8M 14.6M 989M 102M 39.66M 506M 38.76M 37.92M 1.62B
Net Debt -46.2M -32.45M -28.47M -26.89M -24.51M -45.87M -3.11B -322M -125M -1.59B -122M -119M -5.11B -58.4M -41.01M -35.99M -33.99M -30.98M -57.99M -3.93B -407M -158M -2.01B -154M -151M -6.45B
Logo Starpharma Holdings Limited
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
Employees
50
Date Price Change Volume
25/09/26 A$0.8400 +3.07% 3,062,860
24/09/26 A$0.8150 0.00% 1,510,635
23/09/26 A$0.8150 +0.62% 3,219,304
22/09/26 A$0.8100 +1.89% 4,511,884
21/09/26 A$0.7950 -0.63% 2,893,139
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8400AUD
Average target price
1.250AUD
Spread / Average Target
+48.81%

Annual profits - Rate of surprise